AGMB-129
- Generic Name
- AGMB-129
Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Agomab Spain S.L.
- Target Recruit Count
- 25
- Registration Number
- NCT06397508
- Locations
- 🇧🇪
SGS Belgium, Edegem, Belgium
Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Agomab Spain S.L.
- Target Recruit Count
- 14
- Registration Number
- NCT05937386
- Locations
- 🇧🇪
SGS Belgium, Edegem, Belgium
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Phase 2
Active, not recruiting
- Conditions
- Fibrostenotic Crohn's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Agomab Spain S.L.
- Target Recruit Count
- 103
- Registration Number
- NCT05843578
- Locations
- 🇮🇹
University Polyclinic Foundation "Agostino Gemelli", Rome, Italy
🇵🇱Specialist Gastrology Centre GASTROMED, Białystok, Poland
🇵🇱Vita Longa Sp. z.o.o., Katowice, Poland
First in Human Study of ORG-129 in Healthy Volunteers
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Origo Biopharma
- Target Recruit Count
- 81
- Registration Number
- NCT04933565
- Locations
- 🇪🇸
Institut de Recerca de l'Hospital de la Santa Creu i de Sant Pau, Barcelona, Catalonia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath